1
![Zynerba Pharmaceuticals]()
![Zynerba Pharmaceuticals]()
![Zynerba Pharmaceuticals]()
Zynerba Pharmaceuticals
#7164
Rank
$19.02M
Marketcap
United States
Country
Leadership team
Mr. Armando Anido MBA (Chairman & CEO)
Ms. Terri B. Sebree (Pres)
Mr. James E. Fickenscher (CFO & VP of Corp. Devel.)
Products/ Services
Biotechnology, Developer Tools, Pharmaceutical, Product Design
Headquarters
Devon, Pennsylvania, United States
Established
2007
Company Registration
SEC CIK number: 0001621443
Traded as
ZYNE
Overview
Location
Summary
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
History
Zynerba Pharmaceuticals was founded in 2007 and is based in Devon, Pennsylvania. In 2016, Zynerba completed its initial public offering of common stock, and currently trades on the Nasdaq Global Market and the Toronto Stock Exchange (TSX: ZYNE).
Mission
Zynerba Pharmaceuticals’ mission is to develop cannabinoid-based medicines to treat a variety of refractory neurological and psychiatric diseases, including Fragile X Syndrome, Tourette Syndrome, and Autism Spectrum Disorder
Vision
Zynerba Pharmaceuticals’ vision is to create innovative cannabinoid-based medicines for patients around the world who are suffering from these debilitating and refractory neurological and psychiatric diseases.
Key Team
Mr. Albert P. Parker II (Chief Legal Officer & Corp. Sec.)
Mr. Joseph Apostolico (VP of HR)
Recognition and Awards
Zynerba has been awarded the 2019 Scrip Awards Pharmaceutical Company of the Year and is a 2020 Fast Company Most Innovative Company Award recipient.
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Leadership team
Mr. Armando Anido MBA (Chairman & CEO)
Ms. Terri B. Sebree (Pres)
Mr. James E. Fickenscher (CFO & VP of Corp. Devel.)
Products/ Services
Biotechnology, Developer Tools, Pharmaceutical, Product Design
Headquarters
Devon, Pennsylvania, United States
Established
2007
Company Registration
SEC CIK number: 0001621443
Traded as
ZYNE